A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
PHASE3
This Phase 3 study is conducted to evaluate lanifibranor in adults with NAS...
Status
Active Not Recruiting
Location
Objective Health - Birmingham Gastroenterology Associates
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
PHASE2
The study in the T2DM population is intended to confirm the lanifibranor ef...